Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia

International Journal of Antimicrobial Agents

Volumn 45, Issue 5, 2015, Pages 541-544

  Aitken, Samuel L ^a,d   Altshuler, Jerry ^b,e   Guervil, David J ^b   Hirsch, Elizabeth B ^a,f   Ostrosky Zeichner, Luis L ^b,c   Ericsson, Charles D ^b,c   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e YALE NEW HAVEN HOSPITAL   (United States)

^f NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Acinetobacter; Clinical outcomes; Pharmacodynamics; Pharmacokinetics; Pseudomonas

Indexed keywords

ANTIINFECTIVE AGENT; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CREATININE;

ADULT; AGED; CHEMISTRY; FEMALE; HUMAN; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PLASMA; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CREATININE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PLASMA; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84939990622     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.12.018     Document Type: Article

References (15)

1. American Thoracic Society Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
2. V.H. Tam, P.S. McKinnon, R.L. Akins, M.J. Rybak, and G.L. Drusano Pharmacodynamics of cefepime in patients with Gram-negative infections J Antimicrob Chemother 50 2002 425 428
3. V.H. Tam, P.S. McKinnon, R.L. Akins, G.L. Drusano, and M.J. Rybak Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function Antimicrob Agents Chemother 47 2003 1853 1861
4. T.P. Lim, K.R. Ledesma, K.T. Chang, J.G. Hou, A.L. Kwa, and M. Nikolaou, et al. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii Antimicrob Agents Chemother 52 2008 2898 2904
5. P. Van der Auwera, and P.J. Santella Pharmacokinetics of cefepime: a review J Antimicrob Chemother 32 1993 103 115
6. M. Manduru, L.B. Mihm, R.L. White, L.V. Friedrich, P.A. Flume, and J.A. Bosso Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method Antimicrob Agents Chemother 41 1997 2527 2532
7. C. Li, X. Du, J.L. Kuti, and D.P. Nicolau Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections Antimicrob Agents Chemother 51 2007 1725 1730
8. J.L. Crandon, C.C. Bulik, J.L. Kuti, and D.P. Nicolau Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa Antimicrob Agents Chemother 54 2010 1111 1116
9. S.H. MacVane, J.L. Kuti, and D.P. Nicolau Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia Antimicrob Agents Chemother 58 2014 1359 1364
10. E. Boselli, D. Breilh, F. Duflo, M.C. Saux, R. Debon, and D. Chassard, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia Crit Care Med 31 2003 2102 2106
11. M.N. Dudley, P.G. Ambrose, S.M. Bhavnani, W.A. Craig, M.J. Ferraro, and R.N. Jones, et al. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam Clin Infect Dis 56 2013 1301 1309
12. K.A. Bauer, J.E. West, J.M. O'Brien, and D.A. Goff Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections Antimicrob Agents Chemother 57 2013 2907 2912
13. J. Altshuler, S.L. Aitken, D. Guervil, D. Esaian, J. Papadopoulos, and C.A. Arias Treatment of extended-spectrum β-lactamase Enterobacteriaceae with cefepime: the dose matters, too Clin Infect Dis 57 2013 915 916
14. J.G. Muscedere, A. Day, and D.K. Heyland Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia Clin Infect Dis 51 2010 S120 S125
15. G. Richards, H. Levy, P.F. Laterre, C. Feldman, B. Woodward, and B.M. Bates, et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS J Intensive Care Med 26 2011 34 40